NCT06330012Recruiting
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Source: ClinicalTrials.gov · Last updated 26 Mar 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 19 Mar 2024
- Start date
- 18 Mar 2024
- Primary completion date
- 15 Jan 2025
- Lead sponsor
- Samsung Medical Center
- Diseases
- Childhood cancers
- NCT number
- NCT06330012
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 18 Mar 2024 to the primary completion date, 15 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- TNBC breast cancer
- Hormone receptor positive breast cancer
Other
- Non-available FFPE samples
- Treated except T-Dxd
Who the study is looking for
- HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ji-Yeon Kim Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.